Resultados totales (Incluyendo duplicados): 34357
Encontrada(s) 3436 página(s)
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717
. 2017

SAFETY AND VACCINE-INDUCED HIV-1 IMMUNE RESPONSES IN HEALTHY VOLUNTEERS FOLLOWING A LATE MVA-B BOOST 4 YEARS AFTER THE LAST IMMUNIZATION

  • Guardo, Alberto C
  • Gómez, Carmen Elena
  • Díaz-Brito, Vicens
  • Pich, Judit
  • Arnaiz, Joan Albert
  • Perdiguero, Beatriz
  • GARCIA ARRIAZA, JUAN FRANCISCO
  • González, Nuria
  • Sorzano, Carlos O S
  • Jiménez, Laura
  • Jiménez, José Luis
  • Muñoz-Fernández, María Ángeles
  • Gatell, José M
  • Alcamí, José
  • Esteban, Mariano
  • López Bernaldo de Quirós, Juan Carlos
  • García, Felipe
  • Plana, Montserrat
We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost., Peer reviewed

Proyecto: //
DOI: http://hdl.handle.net/10261/345717, https://api.elsevier.com/content/abstract/scopus_id/85032215204
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717
HANDLE: http://hdl.handle.net/10261/345717, https://api.elsevier.com/content/abstract/scopus_id/85032215204
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717
PMID: http://hdl.handle.net/10261/345717, https://api.elsevier.com/content/abstract/scopus_id/85032215204
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717
Ver en: http://hdl.handle.net/10261/345717, https://api.elsevier.com/content/abstract/scopus_id/85032215204
Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345717

Digital.CSIC. Repositorio Institucional del CSIC
oai:digital.csic.es:10261/345726
. 2011

SAFETY AND IMMUNOGENICITY OF A MODIFIED POX VECTOR-BASED HIV/AIDS VACCINE CANDIDATE EXPRESSING ENV, GAG, POL AND NEF PROTEINS OF HIV-1 SUBTYPE B (MVA-B) IN HEALTHY HIV-1-UNINFECTED VOLUNTEERS: A PHASE I CLINICAL TRIAL (RISVAC02)

  • García, Felipe
  • Bernaldo de Quirós, Juan Carlos López
  • Gómez, Carmen E
  • Perdiguero, Beatriz
  • Nájera, Jose L
  • Jiménez, Victoria
  • GARCIA ARRIAZA, JUAN FRANCISCO
  • Guardo, Alberto C
  • Pérez, Iñaki
  • Díaz-Brito, Vicens
  • Conde, Matilde Sánchez
  • González, Nuria
  • Alvarez, Amparo
  • Alcamí, José
  • Jiménez, José Luis
  • Pich, Judit
  • Arnaiz, Joan Albert
  • Maleno, María J
  • León, Agathe
  • Muñoz-Fernández, María Angeles
  • Liljeström, Peter
  • Weber, Jonathan
  • Pantaleo, Giuseppe
  • Gatell, José M
  • Plana, Montserrat
  • Esteban, Mariano
To investigate the safety and immunogenicity of a modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B), a phase-I, doubled-blind placebo-controlled trial was performed., Peer reviewed

Proyecto: //
DOI: